Skip to main content
. 2006 Jan 21;332(7534):152–155. doi: 10.1136/bmj.332.7534.152

Fig 2.

Fig 2

Anticyclic citrullinated peptides in patients with early rheumatoid arthritis before clinical onset of disease. Anticyclic citrullinated peptide should be measured if patients are not being referred (still at pilot stage), as this is a strong predictor of persistence and the need for assessment. Adapted from Rantapaa-Dahlqvist et al6